As the CannTrust Holdings (NYSE:CTST,TSX:TRST) scandal continues, new revelations about the activity of company executives have come to light.

A new report indicates that CannTrust executives secured millions in gains from insider selling last November after the circulation of an internal email about the company’s improper growing.


The Canadian company has weathered turmoil since Health Canada discovered earlier this month that it had been growing cannabis in unlicensed rooms at its facility in Pelham, Ontario.

Since the original announcement by the firm on July 8, shares of CannTrust have seen a nosedive in value of over 50 percent both in New York and Toronto.

The company is now awaiting a decision from Health Canada, the regulatory body tasked with overseeing the marijuana industry, on the status of its licensed operations.

The latest news shows that according to selling and buying activity records, two executives at the firm, former board chair Eric Paul, who also previously served as CEO of the company, and Mark Litwin, a director, sold about C$1 million worth of shares on November 16 of last year.

That is the same day an internal email showed Paul was aware of the irregular growing, according to a Globe and Mail report.

Paul was asked to resign on July 25, at the same time Peter Aceto, former CEO of the company, was fired.

The Globe and Mail report also points to the selling of C$5 million worth of CannTrust shares by Cannamed Financial, a holding company, after the email went out.

On Monday (July 29), Bloomberg reported that Aceto has been stripped of approximately C$8.2 million worth of stock options in the company.

The report indicates that his options will most likely be canceled; however, in the case that they are not, the performance of the stock isn’t helping Aceto’s cause. The news outlet states:

According to the options awarded to Aceto when he joined the company in October, a third were to be vested annually in one-third increments, with two-thirds to be vested based on achieving share price milestones of $15 to $25 over three years.

As mentioned, the market is now preparing for a ruling from Health Canada on the status of CannTrust’s operations. The company has filed a review package with the federal agency.

As of 3:41 p.m. EDT on Tuesday (July 30), shares of the company were trading down 0.92 and 0.35 percent at US$2.15 and C$2.85 in New York and Toronto, respectively.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less
  • Distinguished economist and former CEO of Ecopetrol, Colombia’s largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500
  • Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy
  • Adds proven economic and international business experience to boost the global growth of the Khiron business model
  • Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1 st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces that Mr. Juan Carlos Echeverry has been appointed to the Board of Directors of the Company, effective immediately. Mr. Echeverry brings extensive corporate, academic and macroeconomic experience, serving as Colombia’s Minister of Finance from 2010 to 2012 and as the CEO and President of Ecopetrol from 2015 to 2017.

Keep reading... Show less

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less